Oncology Business Management | Specialty

FDA Grants Full Approval to Osimertinib for T790M+ NSCLC

March 31st 2017

The FDA has granted a regular approval to osimertinib as a treatment for patients with metastatic EGFR T790M mutation-positive non–small cell lung cancer following prior treatment with an EGFR TKI, based on progression-free survival findings from the phase III AURA3 trial.

ACCC Calls for Vigilance Despite Repeal Failure

March 30th 2017

The Republican-led Affordable Care Act repeal and replace effort has the potential to be revived, but majority leaders may not want to risk further political capital in a battle that could go against them, speakers said at this year's Association of Community Cancer Centers' CANCERSCAPE annual conference.

ASCO Fights Perception That Independents Get Short Shrift

March 30th 2017

Daniel F. Hayes, MD, and Stephen S. Grubbs, MD, discuss the perception that ASCO has not been truly representative of smaller, independent oncology practices throughout the United States, and how they plan to remedy that.

FDA Grants Priority Review to CTL019 for ALL

March 30th 2017

The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.

FDA Panel Supports Subcutaneous Rituximab for Blood Cancers

March 29th 2017

The FDA's Oncologic Drugs Advisory Committee unanimously (11-0) recommended approval of subcutaneous rituximab for the treatment of patients with certain blood cancers.

ASCO Highlights Challenges, Hope in State of Cancer Care Report

March 22nd 2017

The Affordable Care Act has improved access to cancer care for millions of Americans, and many new drugs and new indications for existing cancer drugs were approved in 2016, but there are frontiers in improving cancer care that include information barriers, disparities in the availability of rural care, and stressors on physicians and oncology practices, ASCO said in its annual report State of Cancer Care in America: 2017.

Binimetinib Application for NRAS-Mutant Melanoma Withdrawn

March 20th 2017

Array BioPharma has withdrawn its new drug application for binimetinib as a treatment for patients with NRAS-mutant advanced melanoma, based on feedback from the FDA during a preplanned review meeting.

Big Data May Guide Future Treatment Decisions

March 17th 2017

The paucity of patients participating in clinical trials makes data extrapolation and application complex, calling for a need to explore health technology solutions that tap the potential of real-world data.

MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer

March 14th 2017

Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

Pecora Recognized for Innovation in Medicine

March 14th 2017

Andrew L. Pecora, MD, has been awarded the inaugural Rosemarie J. Sorce Endowed Chair in Innovation at Hackensack Meridian Health.

Study Shows Healthcare Utilization and Costs for mTNBC

March 11th 2017

Healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer, indicating a need for better targeted treatments for this patient class.

A Change of Horses in Midstream

March 5th 2017

The Affordable Care Act has given rise to healthcare upon which many now depend. Those with an ear to the tracks in Washington, DC, believe that something new is definitely on the way.

Dr. Oh on the Sequencing of New Therapies for Prostate Cancer

February 24th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).

Midwest Oncology Practice Succeeds With Independent Spirit

February 23rd 2017

The partners at Cancer Center of Kansas have heard for years about all the radical changes they must make to survive as a business. They have implemented those changes required by law, but they have stood firm against fads.

Share the Responsibility or Share the Suffering

February 23rd 2017

Andrew L. Pecora, MD, discusses his hopes for healthcare reform if the the Affordable Care Act is repealed.

Specialty Pharmacy: Build, Buy, or Partner

February 22nd 2017

For oncology practices that want to expand specialty pharmacy services on behalf of their patients, should they build, buy, or partner?

Phone Triage Success Is Built With Patience

February 22nd 2017

Oncologists discuss their experience and best practices with phone triage programs.

Final Thoughts on Squamous NSCLC Research

February 21st 2017

EGFR-Targeted Therapy for Squamous NCSLC

February 21st 2017

Further Sequencing in Squamous NSCLC

February 21st 2017